Biology Reference
In-Depth Information
different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major
depressive disorder. Neuropsychobiology 26:59-64
Ford PA, Durham AL, Russell RE, Gordon F, Adcock IM, Barnes PJ (2010) Treatment effects of
low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest 137:1338-1344
Fozard JR, Hannon JP (1999) Adenosine receptor ligands: potential as therapeutic agents in
asthma and COPD. Pulm Pharmacol Ther 12:111-114
Gamble E, Grootendorst DC, Brightling CE, Troy S, Qiu Y, Zhu J, Parker D, Matin D,
Majumdar S, Vignola AM, Kroegel C, Morell F, Hansel TT, Rennard SI, Compton C,
Amit O, Tat T, Edelson J, Pavord ID, Rabe KF, Barnes NC, Jeffery PK (2003) Antiinflamma-
tory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 168:976-982
Gibson LC, Hastings SF, McPhee I, Clayton RA, Darroch CE, Mackenzie A, Mackenzie FL,
Nagasawa M, Stevens PA, Mackenzie SJ (2006) The inhibitory profile of Ibudilast against the
human phosphodiesterase enzyme family. Eur J Pharmacol 538:39-42
Giembycz MA (2001) Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma
and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 10:1361-1379
Giembycz MA (2002) Development status of second generation PDE4 inhibitors for asthma and
COPD: the story so far. Monaldi Arch Chest Dis 57:48-64
Giembycz MA (2008) Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded
optimism or wishful thinking? Br J Pharmacol 155:288-290
Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, Kipnis C (2008) An open-label,
single-arm pilot study in paients with severe plaque-type psoriasis treated with an oral anti-
inflammatory agent, apremilast. Curr Med Res Opin 24:1529-1538
Grootendorst DC, Gauw SA, Baan R, Kelly J, Murdoch RD, Sterk PJ, Rabe KF (2003) Does a
single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in
patients with chronic obstructive pulmonary disease? Pulm Pharmacol Ther 16(115-120):2003
Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbr
oker D, Bethke TD,
Hiemstra PS, Rabe KF (2007) Reduction in sputum neutrophil and eosinophil numbers by the
PDE4 inhibitor roflumilast in patients with COPD. Thorax 62:1081-1087
Gutke HJ, Guse JH, Khobzaoui M, Renukappa-Gutke T, Burnet M (2005) AWD-12-281 (inhaled)
(elbion/GlaxoSmithKline). Curr Opin Investig Drugs 6:1149-1158
Hanania NA, Brose M, Larsson T, Rabe KF (2010) Efficacy of roflumilast in patients receiving
concomitant treatments for chronic obstructive pulmonary disease over 12 months. Am J
Respir Crit Care Med 181:4435
Hatzelmann A, Schudt C (2001) Anti-inflammatory and immunomodulatory potential of the novel
PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297:267-279
Hatzelmann A, Morcillo EC, Lungarella G, Adnot S, Shahin S, Rolf B, Schudt C, Hermann T
(2010) The preclinical pharmacology of roflumilast - a selective, oral phosphodiesterase 4
inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther
23:235-326
Hauns B, Hermann R, Hunnemeyer A, Herzog R, Hauschke D, Zech K, Bethke TD (2006)
Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-
daily phosphodiesterase 4 inhibitor, in healthy subjects. J Clin Pharmacol 46:1146-1153
Harbinson PL, MacLeod D, Hawskworth R, O'Toole S, Sullivan PJ, Heath P, Kilfeather S, Page
CP, Costello J, Holgate ST, Lee T (1997) The effect of a novel orally active selective PDE4
isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur Respir
J 10:1008-1014
Hebenstreit GF, Fellerer K, Fichte K, Fischer G, Geyer N, Meya U, Sastre-y-Hernandez M,
Schony W, Schwartzer M, Soukop W, Trampitsch E, Varosanec S, Zawada E, Zochling R
(1989) Rolipram in major depressive disorder: results of a double-blind comparative study with
imipramine. Pharmacopsychiatry 22:156-160
Hermann R, Lahu G, Huennemeyer A, Knoerzer D, Bethke TD, Haverkamp W (2006a) No effect
of roflumilast on cardiac repolarization in healthy subjects. Eur Respir J 28(Suppl 50):660s
€
